Pyrrolopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases

US8987268B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Stephen T. Wrobleski · Whitehouse Station, US
• Jagabandhu Das · Mercerville, US
• Jingwu Duan · Yardley, US
• Junqing Guo · Princeton, US
• John Hynes · Washington Crossing, US
• Bin Jiang · Norristown, US
• James Kempson · Princeton, US
• Shuqun Lin · Newtown, US
• Zhonghui Lu · King of Prussia, US
• William J. Pitts · Newtown, US
• Steven H. Spergel · Warrington, US
• Hong Wu · Meekrap-oord, CN
• Bingwei Yang · Montgomery, US

Key dates

• Filing date: Mar 16, 2012
• Grant date: Mar 24, 2015
• Expiry date: Mar 16, 2032

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D519/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of JAK3, thereby making them useful for the treatment of inflammatory and autoimmune diseases.